While Romilkimab, which blocks IL-4 and IL-13, has been shown to effectively reduce dermal thickening in systemic sclerosis, it has not been shown to significantly improve lung function, underscoring the challenge of reversing fibrosis once established [101]. Here, IL4 is linked to systemic sclerosis.